195 related articles for article (PubMed ID: 35042460)
21. Changes in physical functioning and muscle strength in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison.
Gonzalez BD; Jim HSL; Small BJ; Sutton SK; Fishman MN; Zachariah B; Heysek RV; Jacobsen PB
Support Care Cancer; 2016 May; 24(5):2201-2207. PubMed ID: 26563183
[TBL] [Abstract][Full Text] [Related]
22. Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism.
Klil-Drori AJ; Yin H; Tagalakis V; Aprikian A; Azoulay L
Eur Urol; 2016 Jul; 70(1):56-61. PubMed ID: 26138040
[TBL] [Abstract][Full Text] [Related]
23. Cardiovascular and Skeletal-related Events Following Localized Prostate Cancer Treatment: Role of Surgery, Radiotherapy, and Androgen Deprivation.
Wallis CJ; Mahar AL; Satkunasivam R; Herschorn S; Kodama RT; Lee Y; Kulkarni GS; Narod SA; Nam RK
Urology; 2016 Nov; 97():145-152. PubMed ID: 27502032
[TBL] [Abstract][Full Text] [Related]
24. Effects of recreational soccer in men with prostate cancer undergoing androgen deprivation therapy: study protocol for the 'FC Prostate' randomized controlled trial.
Uth J; Schmidt JF; Christensen JF; Hornstrup T; Andersen LJ; Hansen PR; Christensen KB; Andersen LL; Helge EW; Brasso K; Rørth M; Krustrup P; Midtgaard J
BMC Cancer; 2013 Dec; 13():595. PubMed ID: 24330570
[TBL] [Abstract][Full Text] [Related]
25. Muscle and bone effects of androgen deprivation therapy: current and emerging therapies.
Cheung AS; Zajac JD; Grossmann M
Endocr Relat Cancer; 2014 Oct; 21(5):R371-94. PubMed ID: 25056176
[TBL] [Abstract][Full Text] [Related]
26. Evidence for reduced neuromuscular function in men with a history of androgen deprivation therapy for prostate cancer.
Girard D; Marino FE; Cannon J
Clin Physiol Funct Imaging; 2014 May; 34(3):209-17. PubMed ID: 24119067
[TBL] [Abstract][Full Text] [Related]
27. Risk of developing hypertension after hormone therapy for prostate cancer: a nationwide propensity score-matched longitudinal cohort study.
Wu YH; Jhan JH; Ke HL; Tseng SI; Chang YH; Yeh HC; Li CC; Lee YC
Int J Clin Pharm; 2020 Dec; 42(6):1433-1439. PubMed ID: 32951178
[TBL] [Abstract][Full Text] [Related]
28. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.
Braga-Basaria M; Dobs AS; Muller DC; Carducci MA; John M; Egan J; Basaria S
J Clin Oncol; 2006 Aug; 24(24):3979-83. PubMed ID: 16921050
[TBL] [Abstract][Full Text] [Related]
29. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.
Malcolm JB; Derweesh IH; Kincade MC; DiBlasio CJ; Lamar KD; Wake RW; Patterson AL
Can J Urol; 2007 Jun; 14(3):3551-9. PubMed ID: 17594745
[TBL] [Abstract][Full Text] [Related]
30. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
Galvão DA; Spry NA; Taaffe DR; Newton RU; Stanley J; Shannon T; Rowling C; Prince R
BJU Int; 2008 Jul; 102(1):44-7. PubMed ID: 18336606
[TBL] [Abstract][Full Text] [Related]
31. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.
Saigal CS; Gore JL; Krupski TL; Hanley J; Schonlau M; Litwin MS;
Cancer; 2007 Oct; 110(7):1493-500. PubMed ID: 17657815
[TBL] [Abstract][Full Text] [Related]
32. Hormone therapy for prostate cancer increases the risk of Alzheimer's disease: a nationwide 4-year longitudinal cohort study.
Jhan JH; Yang YH; Chang YH; Guu SJ; Tsai CC
Aging Male; 2017 Mar; 20(1):33-38. PubMed ID: 28067607
[TBL] [Abstract][Full Text] [Related]
33. Body composition, fatigue and exercise in patients with prostate cancer undergoing androgen-deprivation therapy.
Newton RU; Jeffery E; Galvão DA; Peddle-McIntyre CJ; Spry N; Joseph D; Denham JW; Taaffe DR
BJU Int; 2018 Dec; 122(6):986-993. PubMed ID: 29750398
[TBL] [Abstract][Full Text] [Related]
34. Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer.
Nascimento B; Miranda EP; Jenkins LC; Benfante N; Schofield EA; Mulhall JP
J Sex Med; 2019 Jun; 16(6):872-879. PubMed ID: 31080102
[TBL] [Abstract][Full Text] [Related]
35. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
[TBL] [Abstract][Full Text] [Related]
36. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
[TBL] [Abstract][Full Text] [Related]
37. Adverse effects of androgen deprivation therapy and strategies to mitigate them.
Nguyen PL; Alibhai SM; Basaria S; D'Amico AV; Kantoff PW; Keating NL; Penson DF; Rosario DJ; Tombal B; Smith MR
Eur Urol; 2015 May; 67(5):825-36. PubMed ID: 25097095
[TBL] [Abstract][Full Text] [Related]
38. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
39. Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer.
Lage MJ; Barber BL; Markus RA
Urology; 2007 Dec; 70(6):1104-8. PubMed ID: 18158027
[TBL] [Abstract][Full Text] [Related]
40. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?
Grossmann M; Zajac JD
Clin Endocrinol (Oxf); 2011 Mar; 74(3):289-93. PubMed ID: 21092052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]